Search Results - "GAZIEL, Avital"

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival by SEGURA, Miguel F, BELITSKAYA-LEVY, Ilana, OSMAN, Iman, HERNANDO, Eva, ROSE, Amy E, ZAKRZEWSKI, Jan, GAZIEL, Avital, HANNIFORD, Douglas, DARVISHIAN, Farbod, BERMAN, Russell S, SHAPIRO, Richard L, PAVLICK, Anna C

“…To identify a melanoma microRNA (miRNA) expression signature that is predictive of outcome and then evaluate its potential to improve risk stratification when…”
Get full text

Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration by Magadum, Ajit, Singh, Neha, Kurian, Ann Anu, Munir, Irsa, Mehmood, Talha, Brown, Kemar, Sharkar, Mohammad Tofael Kabir, Chepurko, Elena, Sassi, Yassine, Oh, Jae Gyun, Lee, Philyoung, Santos, Celio X.C., Gaziel-Sovran, Avital, Zhang, Guoan, Cai, Chen-Leng, Kho, Changwon, Mayr, Manuel, Shah, Ajay M., Hajjar, Roger J., Zangi, Lior

“…BACKGROUND:The adult mammalian heart has limited regenerative capacity, mostly attributable to postnatal cardiomyocyte cell cycle arrest. In the last 2…”
Get full text

In Vivo miRNA Decoy Screen Reveals miR-124a as a Suppressor of Melanoma Metastasis by Moubarak, Rana S, Koetz-Ploch, Lisa, Mullokandov, Gavriel, Gaziel, Avital, de Pablos-Aragoneses, Ana, Argibay, Diana, Kleffman, Kevin, Sokolova, Elena, Berwick, Marianne, Thomas, Nancy E, Osman, Iman, Brown, Brian D, Hernando, Eva

“…Melanoma is a highly prevalent cancer with an increasing incidence worldwide and high metastatic potential. Brain metastasis is a major complication of the…”
Get full text

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy by SEGURA, Miguel F, FONTANALS-CIRERA, Bárbara, DARVISHIAN, Farbod, OHLMEYER, Michael, OSMAN, Iman, ZHOU, Ming-Ming, HERNANDO, Eva, GAZIEL-SOVRAN, Avital, GUIJARRO, María V, HANNIFORD, Doug, GUANGTAO ZHANG, GONZALEZ-GOMEZ, Pilar, MORANTE, Marta, JUBIERRE, Luz, WEIJIA ZHANG

“…Metastatic melanoma remains a mostly incurable disease. Although newly approved targeted therapies are efficacious in a subset of patients, resistance and…”
Get full text

A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis by Hanniford, Doug, Zhong, Judy, Koetz, Lisa, Gaziel-Sovran, Avital, Lackaye, Daniel J, Shang, Shulian, Pavlick, Anna, Shapiro, Richard, Berman, Russell, Darvishian, Farbod, Shao, Yongzhao, Osman, Iman, Hernando, Eva

“…Brain metastasis is the major cause of mortality among patients with melanoma. A molecular prognostic test that can reliably stratify patients at initial…”
Get full text

miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis by Gaziel-Sovran, Avital, Segura, Miguel F., Di Micco, Raffaella, Collins, Mary K., Hanniford, Douglas, Vega-Saenz de Miera, Eleazar, Rakus, John F., Dankert, John F., Shang, Shulian, Kerbel, Robert S., Bhardwaj, Nina, Shao, Yongzhao, Darvishian, Farbod, Zavadil, Jiri, Erlebacher, Adrian, Mahal, Lara K., Osman, Iman, Hernando, Eva

“…To metastasize, a tumor cell must acquire abilities such as the capacity to colonize new tissue and evade immune surveillance. Recent evidence suggests that…”
Get full text

ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1 by Horn, Galit, Gaziel, Avital, Wreschner, Daniel H., Smorodinsky, Nechama I., Ehrlich, Marcelo

“…Epithelial to mesenchymal transition (EMT) integrates changes to cell morphology and signaling pathways resulting from modifications to the cell's…”
Get full text

miRNA-mediated GALNT modulation of invasion and immune suppression: A sweet deal for metastatic cells by Gaziel-Sovran, Avital, Hernando, Eva

“…Glycosylation is a key process impacting on many aspects of cellular interactions. We recently reported that a miRNA cluster controls glycosylation by directly…”
Get full text

The transformative role of digital health platforms: Bridging diversity gaps in cancer care in younger patient populations by Lapidot, Yelena, Gaziel, Avital, Bader, Tzvia

“…e13503 Background: Digital health platforms are transforming cancer care by offering unprecedented access to treatment options, including clinical trials…”
Get full text

Bridging the gap: Leveraging AI to enhance access to clinical trials for underrepresented and underserved populations with cancer by Gaziel, Avital, Lapidot, Yelena, Bader, Tzvia

“…e13701 Background: National guidelines emphasize the crucial role of clinical trials (CTs) participation for all cancer patients. Despite this, significant…”
Get full text

In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis by Gaziel-Sovran, Avital, Osman, Iman, Hernando, Eva

“…Brain metastasis (B-Met) from melanoma remains mostly incurable and the main cause of death from the disease. Early stage clinical trials and case studies show…”
Get full text

Barriers to diversity in cancer therapy: Uncovering disparities in knowledge and interpretation of genetic testing among African Americans, and their direct implications for access to mutation-based therapies by Lapidot, Lena, Safran, Michal, Bader, Tzvia, Gaziel, Avital

“…e18587 Background: African American cancer patients are disproportionately impacted by limited access to health education and resources, limiting their access…”
Get full text

ECOG score as a barrier for clinical trial eligibility in the patient population with genitourinary cancer: Is it time to adapt this criterion to real-world data? by Gortzak Uzan, Limor, Lapidot, Lena, Bader, Tzvia, Gaziel, Avital

“…78 Background: ECOG score is a common eligibility criteria used in clinical trials (CT). Many CT recruit only patients in good physical condition (ie. minimal…”
Get full text

Patients with prostate cancer consider clinical trial options significantly earlier in their journey compared to patients with other solid tumors by Edry-Botzer, Liat, Lapidot, Yelena, Katz, Hanna, Bader, Tzvia, Gaziel, Avital

“…305 Background: A common misconception is that oncology clinical trials (CT) are a last resort for those who have exhausted treatments or are in advanced…”
Get full text

Can an artificial intelligence-based platform reduce physician burden and increase access to clinical trials? by Gortzak Uzan, Limor, Lichtenfeld, J. Leonard Leonard, Bader, Tzvia, Gaziel, Avital

“…1552 Background: Clinical trials for cancer patients are an important treatment option and a resource for drug development. Although patients are more actively…”
Get full text

Development and characterization of a clinically relevant mouse model of melanoma brain metastasis by Morsi, Amr, Gaziel-Sovran, Avital, Cruz-Munoz, William, Kerbel, Robert S., Golfinos, John G., Hernando, Eva, Wadghiri, Youssef Z.

Get full text

Abstract PO3-10-07: Leveraging AI to identify factors influencing access to care and their association with overall survival- a multiracial Breast Cancer cohort by Safran, Michal, Lapidot, Yelena, Bader, Tzvia, Gaziel, Avital

“…Introduction: Data from the Centers for Disease Control and Prevention (CDC) labels each US state based on its 5-Year Relative Survival of Breast Cancer (BC)…”
Get full text

Abstract A119: Unveiling disparities in clinical trial participation: Exploring socioeconomic barriers and access to insurance among diverse ethnic groups by Jubran, Ritta, Lapidot, Yelena, Bader, Tzvia, Gaziel, Avital

“…Introduction: Diversity in clinical trials (CTs) is crucial for enhancing the ability to generalize research findings and promote equal health services for…”
Get full text

Profound impact of ECOG performance status on clinical trial eligibility and access: Diverging effects by cancer type by Lapidot, Yelena, Safran, Michal, Bader, Tzvia, Gaziel, Avital

“…97 Background: The Eastern Cooperative Oncology Group (ECOG) performance status is a widely used measure of a patient's (pt) physical function and is often…”
Get full text

Abstract P2-13-05: Triple Negative Breast Cancer (TNBC) patients are more likely to digitally explore clinical trial options and prior to receiving treatment for advanced disease compared to non-TNBC patients by Safran, Michal, Lapidot, Yelena, Bader, Tzvia, Gaziel, Avital

“…Introduction: Triple-negative breast cancer (TNBC), an aggressive form of breast cancer (BC) that is associated with poor prognosis, accounts for 10-15% of all…”
Get full text